Class Action Lawsuit Filed Against Iovance Biotherapeutics Over Alleged Stock Inflation

Levi & Korsinsky initiated a class action lawsuit against Iovance Biotherapeutics (IOVA) on May 15, 2025, on behalf of shareholders who purchased stock between August 8, 2024, and May 8, 2025. The plaintiffs claim they bought shares at artificially inflated prices and are now seeking compensation for financial losses.

Iovance, a commercial-stage biotech firm specializing in oncology, has launched two treatments in the U.S. market: Amtagvi, the first FDA-approved T cell therapy for advanced melanoma, and Proleukin, an interleukin-2 product used alongside Amtagvi. The lawsuit centers on the company's allegedly misleading claims about the commercial potential of these therapies.

Investors who acquired IOVA stock during the specified period may join the litigation. The case underscores the risks of biotech investments, where clinical promise and regulatory milestones often dictate market valuations.